Observe Closely (1)pentobarbital will decrease the level or result of fentanyl intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Closely. Coadministration of fentanyl with CYP3A4 inducers may lead to the decrease in fentanyl plasma concentrations, deficiency of efficacy or, possibly, enhancement of the withdrawal syndrome in the affected individual who may have developed Actual physical dependence to fentanyl. Right after halting a CYP3A4 inducer, as the consequences on the inducer decline, the fentanyl plasma concentration will improve which could raise or lengthen both of those the therapeutic and adverse outcomes.
pentobarbital will lessen the extent or influence of triazolam by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will reduce the level or effect of cyclosporine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital will reduce the extent or outcome of venetoclax by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will minimize the extent or influence of more info phenytoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Check.
pentobarbital will decrease the extent or influence of atogepant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Intently. Proposed atogepant dosage with concomitant use of strong or average CYP3A4 inducers is thirty mg or 60 mg qDay.
pentobarbital will decrease the level or influence of brexpiprazole by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Intently. Double brexpiprazole dose above one-two weeks if administered with a powerful CYP3A4 inducer.
fentanyl transdermal and pentobarbital each maximize sedation. Stay away from or Use Alternate Drug. Restrict use to clients for whom substitute treatment method selections are insufficient
pentobarbital will lessen the level or outcome of disopyramide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unidentified.
pentobarbital will decrease the extent or outcome of efavirenz by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unknown.
pentobarbital will reduce the level or impact of pitolisant by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Carefully. Pitolisant exposure is diminished by fifty% if coadministered with potent CYP3A4 inducers.
pentobarbital will decrease the extent or result of nelfinavir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will reduce the extent or influence of atorvastatin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
pentobarbital will decrease the level or effect of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.